Covering Executive Director

Dr Ichiro Hirao

Dr Ichiro Hirao
Covering Executive Director
Institute of Bioengineering and Nanotechnology

The Institute of Bioengineering and Nanotechnology (IBN) was established in 2003 by Professor Jackie Y. Ying. Under her leadership, IBN contributed significantly to the development of Singapore’s research capabilities through scientific breakthroughs and innovations. The Institute established numerous industrial, clinical and academic collaborations and 13 spin-off companies to commercialize its technologies. It also played an important role in nurturing future research talents through its Youth Research Program.

In April 2018, as part of a leadership renewal process, Professor Ying stepped down from IBN to lead A*STAR’s new NanoBio Lab, and Dr. Ichiro Hirao became IBN’s Covering Executive Director. IBN will continue to capitalize on its multidisciplinary research approach to develop new technologies and products for diagnostics and therapeutics, such as novel nanomedicines, unique biomaterials and systems, tissue and organoid models, and the new research area, xenobiology.

Prior to joining IBN in 2015, Dr. Hirao was a Professor at the University of Tokyo’s Research Center for Advanced Science and Technology and Team Leader of the Synthetic Molecular Biology Team at RIKEN’s Center for Life Science Technologies. Dr. Hirao is a leading scientist in the field of xenobiology and the founding President and CEO of TAGCyx Biotechnologies, a RIKEN spin-off company. His extensive experience and achievements in the cutting-edge and emerging fields of Biotechnology and Xenobiology, specifically his discovery of new DNA base pairs for expanding the genetic alphabet, place him in good stead to lead IBN.


IBN in Numbers

Established in 2003, the Institute of Bioengineering and Nanotechnology (IBN) is the world’s first bioengineering and nanotechnology research institute. IBN’s mission is to conduct multidisciplinary research across science, engineering, and medicine for breakthroughs to improve healthcare and quality of life. IBN’s research activities are focused on Nanomedicine and Biomaterials, Tissue and Organoid Models, Synthetic Xenobiology and Biosystems, and Green and Safe Biomaterials.


Mission and Corporate Values

Since 2003, IBN has carved out a unique niche at the interface of bioengineering and nanotechnology. Founded by Professor Jackie Y. Ying, the Institute conducts interdisciplinary research bridging science, engineering and medicine. IBN is focused on generating new knowledge and creating innovative technology platforms that combine novel catalytic chemistry, biomaterials, nanofabricated devices, and microfluidic systems with biological and biomedical engineering.

Effective April 1, 2018, Dr Ichiro Hirao has been appointed Covering Executive Director of IBN.

Mission

Corporate Values